Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· QuickByte ScienceAudio: English

Did Scientists Just Find a Real Anti-Aging Switch?

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

About this video

Creator description · original textText language: English

A “New Anti-Aging Drug” in Yeast? What the Rapalink-1 Study Really Shows (Microbiome → mTOR) Headlines say a new class of drug fights aging at the cellular level. The real story: researchers used a next-gen mTOR inhibitor (Rapalink-1) in fission yeast and uncovered a microbiome-linked agmatine → agmatinase → TORC1 feedback that nudges longevity signals. Cool mechanism, not a human anti-aging pill (yet). In this video I break down what happened, why it matters, and what not to do with this news. Read the article: ScienceAlert — “A New Class of Drug Created That Fights Aging on a Cellular Level” https://www.sciencealert.com/a-new-class-of-drug-created-that-fights-aging-on-a-cellular-level Primary paper (open access): Communications Biology (Nature Portfolio) — Kumar, Ng, Rallis (2025) https://www.nature.com/articles/s42003-025-08731-3 Press release / coverage: EurekAlert summary: https://www.eurekalert.org/news-releases/1099727 ⏱️ Chapters 00:00 Hook — “New anti-aging drug?” What actually happened 00:18 The experiment: Rapalink-1 in fission yeast 00:55 mTORC1 refresher: growth vs. maintenance 01:30 The agmatine → agmatinase → TORC1 loop 02:05 What this doesn’t mean for humans (yet) 02:40 Why it matters: microbiome → metabolism → mTOR 03:10 Practical takeaways (no hype, just evidence) 03:35 What to watch next (mammals, biomarkers, safety) 03:55 Credits & sources Key points Model: Schizosaccharomyces pombe (fission yeast), not humans. What’s new: Mechanistic link from agmatine (diet/microbiome) via agmatinase to TORC1 tone and yeast lifespan. What’s not new: mTOR inhibition extending lifespan in lab organisms dates back to rapamycin; Rapalink-1 is a more engineered, TORC1-leaning inhibitor. Do not start agmatine supplements based on a yeast paper; the coverage itself cautions against that. Watch for: replication in mammalian cells/animals, measurable TORC1 biomarkers, and safety data. Tools & pronunciations (for clarity) Say “m-TOR complex one” (mTORC1) on voice-over to avoid TTS saying “tors one.” TORC1 = “TOR complex one.” Disclaimer This video is for education, not medical advice. Don’t start or stop any drug or supplement without talking to your clinician.

QuickByte Science · 4 min · Source published: 2025-10-10

Added to Harbor: 10/30/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…